Perspective Therapeutics doses first patient in [212Pb]VMT01 plus nivolumab combo cohort

Perspective Therapeutics, Inc.

First patient dosed with [212Pb]VMT01 at 1.5 mCi in combination with nivolumab (Opdivo) for MC1R+ metastatic melanoma Phase 1/2a trial.
Earlier monotherapy cohorts showed no dose-limiting toxicities and early signs of anti-tumor activity, presented at SMR October 2024.
FDA granted Fast Track Designation for [212Pb]VMT01 in unresectable or metastatic melanoma with MC1R expression in September 2024.
New cohort explores dual mechanism of targeted alpha-particle therapy plus PD-1 blockade to improve patient outcomes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.